Experimental preclinical study of pandemic H1N1 vaccine "Refluvac"
M. Zaytseva, M. Melikhova, O. Vakunenkova, B. Khayrullin, S. Mamadaliev, G. Kidirbaev, M. Grudinin, M. Stukova, A. Migunov, L. Tsybalova (St. Petersberg, Russian Federation; Gvardeyski, Kazakhstan)
Source: Annual Congress 2010 - Influenza A (H1N1) and other viral infections: therapeutic aspects
Disease area: Respiratory critical care, Respiratory infections
Abstract The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority for the Republic of Kazakhstan. In this study a monovalent influenza A (H1N1) whole-virion aluminum hydroxide adjuvanted pandemic H1N1 vaccine "Refluvac" was developed on the basis of NIBRG-121 strain A/California/7/09 (produced at NIBSC, London). Intraperitoneally administered vaccine preparations (2-dose 2,5, 5 or 10 microg of HA) elicited high HI titers in a dose-dependent manner (hemagglutination inhibition and microneutralization assays). All immunized mice were completely protected against lethal challenge with influenza A/California/7/09 (H1N1). The toxicity study was done on mice and rats. To determine the acute toxicity parameters the "Refluvac" was introduced to white mice and rats of both genders intramusculary in increasing doses. Control animals were introduced with similar volume of dissolvent. Observation period was 14 days. The maximal introduced volume of vaccine equaled to 24 human doses. There were no any lethal effects. The toxicometry results, data of necropsy and animal observations in post-toxication period after acute poisoning suggest that "Refluvac" is related to class V being virtually non-toxic compounds. Double administration of the "Refluvac" to experimental animals in therapeutic dose did not exhibit harmful impact on major adaptive systems (nervous, cardiovascular, hemopoietic, and excretory), metabolism, general state and development, main homeostatic parameters. It should be noted that the "Refluvac" also did not have any irritating and allergenicity effect.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Zaytseva, M. Melikhova, O. Vakunenkova, B. Khayrullin, S. Mamadaliev, G. Kidirbaev, M. Grudinin, M. Stukova, A. Migunov, L. Tsybalova (St. Petersberg, Russian Federation; Gvardeyski, Kazakhstan). Experimental preclinical study of pandemic H1N1 vaccine "Refluvac". Eur Respir J 2010; 36: Suppl. 54, 2986
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: